Healthcare policies have rapidly evolved in recent years, and 2025 was no exception. From payment policies to physician shortages, ASE and other medical societies had plenty to fight for throughout the year.
There is a risk that these catheters will fail to retain their shape during use, causing procedure delays and creating the risk of an adverse outcome. The FDA first warned users about the issue back in August.
Sean Clifford filed the lawsuit Sept. 24, 2024, in the New York State Supreme Court, contending a radiologist failed to spot signs of a forthcoming stroke.
As IR procedure volumes continue to climb, coupled with anesthesiology provider shortages, there is growing interest in achieving “deeper, more reliable sedation.”
A new analysis claims the “benchmark” qualifying payment amount insurers calculate often “dramatically” understates the actual median in-network rates they are paying for in-network care.
In patients with suspected stroke, contrast allergies present a significant dilemma, as contrast-enhanced imaging is often used to guide treatment decisions.
Bottles of duloxetine manufactured by Rising Pharmaceuticals are being recalled due to higher-than-normal levels of nitrosamine contaminants. The recall is classified as Class II, the second most serious type.
Pancreatic cancer is one of the deadliest cancers, with a five-year survival rate of only 44% if caught early, dropping down to 3% if it metastasizes. This is largely due to its ability to elude detection.
While the technology and techniques associated with TAVR have advanced over the years, treating patients who present with baseline atrial fibrillation is still associated with certain risks.
